Every article, report, and earnings note where BMRA appears.
Biomerica's $2.23 million private placement adds shares while the FY2026 filing still carries going-concern language. With revenue down 16.2% and a $3.77 million net loss, the raise buys time but does not establish a turnaround.
Biomerica's $2.23 million financing extends its runway, but it adds roughly 30% to the pre-deal share count without proving the business is turning. With severe losses, negative cash flow, and the stock still below its 200-day average, BMRA remains a dilution trade rather than a turnaround.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate BMRA ReportCancel anytime